For patients with established cardiovascular disease,aspirin is clearly beneficial as part of secondary prevention. However, when used as primary prevention in patients without documented cardiovascular disease, its benefit is much less certain. This podcast will explore 3 recent trials that evaluated aspirin in different populations and found nobenefit for its use as primary prevention.

Join us as we discuss a recent study of push-up capacity in middle-aged men and the association with CVD risk.

In a recent study, data from the Cardiovascular Health Study examined the association between alcohol consumption and incident HF. It was found that moderate alcohol consumption was associated with a survival benefit, implying that individuals 65 years and older with newly diagnosed HF may not need to stop their alcohol use. Join the discussion about these findings and learn how they may impact the care of your patients with HF.

New therapeutic options have emerged in the type 2 diabetes (T2DM) management paradigm that improve hyperglycemic control while decreasing cardiovascular risk. Watch this expert-led 90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and the resultant practical applications for patient care. Participants in this program will also receive expert advice on using ADA and AACE/ACE guidelines appropriately as well as other strategic insights to improve care for their patients with T2DM and cardiovascular risk.

Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin or clopidogrel monotherapy. A new era is emerging in which, by adding low-dose DOACs to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures. In this Virtual Expert Roundtable, the faculty will discuss the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy. In addition to an in-depth look at PAD therapy, participants in this session will receive insights on the latest in secondary prevention options for ESUS and a review of proper dosing for long-term anticoagulation to prevent recurrent events in patients with venous thromboembolic disease.

Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin or clopidogrel monotherapy. A new era is emerging in which, by adding low-dose DOACs to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures. In this Virtual Expert Roundtable, the faculty will discuss the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy.

In this session, you will receive the most important cardiology updates from 2018-2019, including trial evidence for dietary supplements in the prevention of cardiovascular disease and new information about the blood cholesterol guidelines. The session will also provide advice on how to differentiate between opportunistic and systematic screening for atrial fibrillation as well as identify ways to conduct this screening in practice.

This talk will review the new ACC-AHA Hypertension guidelines and emphasize what’s old, what’s new, and what has changed.

Heart failure (HF) affects 5.7 million men and women in the United States, with 915,000 new cases occurring annually and a resultant 1,000,000 hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Mortality with this condition is high, approximately 50% at five years. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This lecture will review the current evidence-based, guideline recommended diagnosis and management of heart failure. The essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management will be discussed.

The epidemiology of acute coronary syndromes has changed dramatically in the past few decades, with lower overall incidence of myocardial infarction (MI) -- particularly ST elevation MI -- and improved survival after an incident MI. The diagnosis and classification of MI is challenging, particularly in the era of sensitive troponin assays. Clinicians must be aware of the frequent occurrence and causes of troponin elevations from conditions other than MI. Following diagnosis, risk stratification for patients with non-ST elevation ACS is critical to making prudent decisions and selecting among the multitude of different options for invasive and medical therapies. When considering potent antiplatelet and antithrombotic therapies, it is of paramount importance to also consider bleeding risk. Primary care clinicians play a critical role in determining the optimal duration of dual antiplatelet therapy, ensuring appropriate use and adherence to evidence-based medical therapies, and addressing lifestyle factors that can help prevent or modify the course after an ACS event.

Get your questions answered by expert faculty in Cardiology. You ask: we listen. You will learn practical solutions to common clinical challenges and tips to apply the latest knowledge in practice.